Hostname: page-component-77f85d65b8-6bnxx Total loading time: 0 Render date: 2026-03-30T10:31:50.246Z Has data issue: false hasContentIssue false

Ten years of percutaneous treatment of sinus venosus defects: evolution of an innovative procedure

Published online by Cambridge University Press:  10 July 2025

Alessia Callegari
Affiliation:
Heart Center and Children’s Research Center, University Children’s Hospital Zurich, Zurich, Switzerland Centre de Référence Malformations Cardiaques Congénitales Complexes—M3C, Hôpital Universitaire Necker-Enfants malades, Assistance Publique—Hôpitaux de Paris, Paris, France
Gareth J. Morgan*
Affiliation:
Department of Pediatrics and Department of Cardiology, University of Colorado, School of Medicine, Colorado, USA
*
Corresponding author: Gareth J. Morgan; Email: Gareth.Morgan@childrenscolorado.org
Rights & Permissions [Opens in a new window]

Abstract

Introduction:

The superior sinus venosus defect is an uncommon CHD, typically associated with partial anomalous pulmonary venous drainage. While surgical correction is the traditional treatment, transcatheter techniques have emerged as a promising alternative. This analysis assesses the evolution of transcatheter correction for superior sinus venosus defect over the past decade, analysing trends on technique, procedural outcomes, and safety.

Methods:

Systematic research identified 23 studies involving approximately 676 patients from 2014 to 2024. Data on demographics, procedural details, and outcomes were extracted, and study quality was assessed using established checklists. Descriptive analyses and trend evaluations were conducted.

Results:

Initially, transcatheter procedures were reserved for high surgical-risk cases, but recent studies emphasise selecting patients with favourable anatomy for interventional closure. Improved screening and patient referral have reduced exclusion rates. While earlier studies utilised 3D printing for planning, later studies increasingly employed periinterventional imaging, particularly CT-fluoroscopy fusion. Balloon-expandable long covered stents, especially custom-made designs, became predominant, with median stent length increasing from 55 mm to 75 mm. Complication rates, including stent embolisation and pulmonary vein obstruction, declined over time.

Conclusions:

Advancements in patient selection, imaging modalities, and procedural techniques have improved the safety and efficacy of transcatheter superior sinus venosus defect correction, reducing reliance on surgical interventions. Custom stents and advanced imaging have played key roles in achieving better outcomes. However, larger studies are required to confirm these findings and evaluate long-term outcomes.

Information

Type
Review
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - SA
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (https://creativecommons.org/licenses/by-nc-sa/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use.
Copyright
© The Author(s), 2025. Published by Cambridge University Press
Figure 0

Figure 1. Distribution of stent types over the years. This bar graph illustrates the percentage distribution of different stent types across various year groups. The predominant stent, represented in blue, is the custom-made 10-zig covered Cheatham-platinum (CP) stent. Other stent types, including the optimus-CVS (orange), 8-zig covered CP stent (light blue), andraStent XXL (green), G-ARMOR stent (red), and covered zephyrXL (purple), are less frequently used but start to appear more prominently in the later years. The x-axis has been condensed between 0–40% to increase the visibility of these newer stent types.

Figure 1

Figure 2. Stent lengths with median trend and IQR over the years. This scatter plot and line graph combination illustrates individual stent lengths (red dots) plotted alongside the median stent length (blue line) for each year. Additionally, the shaded blue region represents the interquartile range (IQR). A gradual increase in stent lengths is observed, with the median stent length rising from around 58 mm in 2018 to approximately 75 mm by 2024. The variability of stent lengths, as indicated by the widening IQR, becomes more pronounced, reflecting an increase in the range of stent lengths used over time. The graph reveals a clear upward trend in stent lengths, with greater variability in the stent selection process in recent years.

Figure 2

Figure 3. Spider chart comparing key aspects of SSVD treatment practices between earlier and later studies. This radar chart illustrates the evolution of superior vena cava syndrome treatment practices by comparing key metrics between earlier (2014–2020) and later studies (2021–2024). favorable anatomy: later studies show an increased focus on selecting patients based on favorable anatomy. Secondary exclusion rate: a lower secondary exclusion rate in later studies indicates improved preliminary screening and patient referral. Advanced imaging: while 3D printing was more common in earlier studies, later studies show increased use of CT-fluoroscopy fusion. Transseptal approach to the pulmonary veins: the transseptal approach became more prevalent in later studies. Non-compliant or mixed balloons: later studies show a more targeted use of compliant and non-compliant balloons. Single custom-made stents: a shift towards using single, long, custom-made covered stents is evident in later studies. Complication rates: later studies report fewer severe complications, such as stent embolisation and tamponade, and lower rates of residual leaks and reinterventions.

Supplementary material: File

Callegari and Morgan supplementary material

Callegari and Morgan supplementary material
Download Callegari and Morgan supplementary material(File)
File 26.4 KB